Health Care • Biotechnology: Pharmaceutical Preparations
$2.23 ▼ -0.04
(-1.76%)
MKT CAP: $38.0M • VOL: 56.9K
52W L $2 52W H $7
ROARABLE / RQD
D- • 43/100
PIOTROSKI
2 / 9
VERU // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-09-30 | FY 2024
FILED 2024-09-30 | FY 2023
FILED 2023-09-30 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $16.9M | $16.3M |
| YoY Revenue Growth % | — | +3.6% | — |
| Gross Profit | — | $5.9M | — |
| Gross Margin % | — | 34.7% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$24.8M | -$36.2M | -$93.8M |
| Operating Margin % | — | -80.0% | -80.0% |
| Net Income (GAAP) | -$22.7M | -$37.8M | -$93.2M |
| EBITDA (Normalized) | -$24.7M | -$36.0M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$30.0M | -$21.7M | -$88.0M |
| Capital Expenditures (CapEx) | $1.1K | $158.3K | — |
| Free Cash Flow (FCF) | -$30.0M | -$21.8M | -$88.0M |
| FCF Margin % | — | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $33.0M | $26.6M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $37.1M | $26.6M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR VERU.